



NDA 21-462

Eli Lilly & Company  
Attention: John F. Worzalla  
Regulatory Research Scientist, U.S. Regulatory Affairs  
Lilly Corporate Center  
Indianapolis, IN 46285

Dear Mr. Worzalla:

Please refer to your new drug application (NDA) dated September 29, 2003, received September 30, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Alimta® (pemetrexed, LY231514).

We acknowledge receipt of your submissions dated October 24, November 22, December 6, 2002; January 10, 28, February 13, March 24, 27, April 3, May 9, 12, 29, June 18, 26, 30, July 29, 30, August 8, 15, 21, 28, September 2, 3, 4, 9, 12, 15, 16, 19, 22, 29, October 6, 7, 20, November 4, 5, 6, 14, 18, 24, 26, December 1, 4, 5, 10, 11, 12, 15, 16, 29, 2003, and January 12, 2004.

This new drug application provides for the use of Alimta® (pemetrexed, LY231514) in the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon attached labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert and the patient package insert). Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format – NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission “**FPL for approved NDA 21-462.**” Approval of this submission by FDA is not required before the labeling is used.

Teva – Fresenius

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Oncology Drug Products and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising  
And Communications, HFD-42  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We have not completed validation of the regulatory methods. However, we expect your continued cooperation to resolve any problems that may be identified.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

The Med-Watch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at [www.fda.gov/medwatch/report/mmp.htm](http://www.fda.gov/medwatch/report/mmp.htm).

If you have any questions, call Patty Garvey, Regulatory Project Manager, at (301) 594-5766.

Sincerely,  
*{See appended electronic signature page}*

Robert Temple, M.D.  
Director  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

Enclosure: labeling

Teva – Fresenius

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Robert Temple  
2/4/04 07:52:20 PM

Teva – Fresenius